Novo Nordisk lifts outlook as oral Wegovy sales boost earnings

Novo Nordisk Wegovy Eli Lilly obesity drug market Q2 earnings

Novo Nordisk reported second‑quarter adjusted operating profit of 33.4 billion Danish crowns, up 11 % year‑on‑year, and beat analysts’ forecasts. The company raised its full‑year profit and sales outlook, citing strong demand for the oral Wegovy weight‑loss pill that launched in the United States in January. Wegovy’s performance helped lift the share price about 35 % from its March low and supports a broader recovery after two years of profit warnings, leadership changes and a 9,000‑job restructuring.

The Danish group also disclosed a non‑cash impairment related to the failed Phase‑3 ZEUS study of the experimental drug Ziltivekimab, which did not meet its primary cardiovascular endpoint. In parallel, Novo Nordisk sued Eli Lilly in a U.S. federal court, accusing the rival of false advertising over its obesity‑drug marketing. Lilly, which still leads the U.S. injectable weight‑loss market, denied the allegations. Analysts estimate the U.S. obesity‑drug market could exceed $100 billion by the end of the decade, making the rivalry a key focus for investors ahead of earnings releases on August 5.

Entities

Corvidia Therapeutics · Eli Lilly and Company · Foundayo (orforglipron) · Mike Doustdar · Novo Nordisk A/S · Wegovy (oral semaglutide) · Wegovy (oral) · Ziltivekimab (ZEUS study) · ziltivekimab

Claims

What the coverage asserts, and how many sources carry each claim.

[● 2 SOURCES] Novo Nordisk’s Phase‑3 ZEUS study of Ziltivekimab failed to meet its primary endpoint. www.sharedeals.de · www.kapitalmarktexperten.de
[● 4 SOURCES] Novo Nordisk’s share price has risen about 35 % from its March low. haber.doviz.com · kfgo.com · econotimes.com
[● 4 SOURCES] Novo Nordisk launched the oral Wegovy weight‑loss pill in the United States in January 2024. haber.doviz.com · econotimes.com · mix929.com · kfgo.com
[● 2 SOURCES] U.S. analysts project the obesity‑drug market to exceed $100 billion by the end of the decade. econotimes.com
[● 2 SOURCES] Novo Nordisk and Eli Lilly will release second‑quarter earnings on August 5, 2024. www.kapitalmarktexperten.de · econotimes.com
[● 2 SOURCES] Eli Lilly’s oral obesity drug Foundayo (orforglipron) competes with Novo Nordisk’s oral Wegovy in the U.S. market. econotimes.com
[● 3 SOURCES] Novo Nordisk cut about 9,000 jobs as part of a restructuring plan. haber.doviz.com · kfgo.com
[● 5 SOURCES] Novo Nordisk filed a U.S. lawsuit accusing Eli Lilly of false advertising. econotimes.com · mix929.com · kelo.com · wkzo.com · wsau.com
[● 4 SOURCES] Novo Nordisk reported Q2 adjusted operating profit of 33.4 billion Danish crowns, up 11 % year‑on‑year. mix929.com · kelo.com · wkzo.com · wsau.com
[● 3 SOURCES] Eli Lilly continues to lead the U.S. injectable weight‑loss drug market. mix929.com · econotimes.com · kfgo.com
[● 4 SOURCES] Novo Nordisk raised its full‑year profit and sales outlook. mix929.com · kelo.com · wkzo.com · wsau.com